Results 11 to 20 of about 122,310 (350)
Neural Regeneration Research, 2016 Rosiglitazone up-regulates caveolin-1 levels and has neuroprotective effects in both chronic and acute brain injury. Therefore, we postulated that rosiglitazone may ameliorate diffuse axonal injury via its ability to up-regulate caveolin-1, inhibit ...
Yong-lin Zhao +5 more
doaj +1 more source
Life, 2021 The processing of the amyloid precursor protein (APP) is a critical event in the formation of amyloid plaques. Platelets contain most of the enzymatic machinery required for APP processing and correlates of intracerebral abnormalities have been ...
Manuel Glauco Carbone +4 more
doaj +1 more source
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice [PDF]
, 2005 Even though the idea that amyloid beta peptide accumulation is the primary event in the pathogenesis of Alzheimer's disease has become the leading hypothesis, the causal link between aberrant amyloid precursor protein processing and tau alterations in ...
Avila, J. (Jesús) +18 more
core +1 more source
Medical Sciences, 2018 The present review analyzes the results of recent clinical trials of β secretase inhibition in sporadic Alzheimer’s disease (SAD), considers the striking dichotomy between successes in tests of β-site Amyloid Precursor Protein-Cleaving ...
Vladimir Volloch, Sophia Rits
doaj +1 more source
Destruxin E Decreases Beta-Amyloid Generation by Reducing Colocalization of Beta-Amyloid-Cleaving Enzyme 1 and Beta-Amyloid Protein Precursor [PDF]
, 2009 Alzheimer-disease-associated beta-amyloid (A beta) is produced by sequential endoproteolysis of beta-amyloid protein precursor (beta APP): the extracellular portion is shed by cleavage in the juxtamembrane region by beta-amyloid-cleaving enzyme (BACE ...
Dohi, Keiji +27 more
core +1 more source
The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease [PDF]
, 2015 Alzheimer's disease (AD) is the most common form of dementia in the elderly and its prevalence is set to increase rapidly in coming decades. However, there are as yet no available drugs that can halt or even stabilize disease progression. One of the main
Baillie, George S. +3 more
core +1 more source
Oxysterol-Binding Protein-1 (OSBP1) Modulates Processing and Trafficking of the Amyloid Precursor Protein [PDF]
, 2008 BACKGROUND Evidence from biochemical, epidemiological and genetic findings indicates that cholesterol levels are linked to amyloid-β (Aβ) production and Alzheimer's disease (AD). Oxysterols, which are cholesterol-derived ligands of the liver X receptors
Abraham, Carmela R. +8 more
core +4 more sources
Aging and Health Research, 2022 With advancements in our ability to treat or manage more diseases than ever, people are able to live longer in greater health. However, for individuals who develop Alzheimer's disease (AD), therapeutic options are currently limited to symptom management ...
Richard J. Elsworthy +3 more
doaj +1 more source
Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. [PDF]
, 2009 The cause(s) of sporadic Alzheimer's disease (sAD) are complex and currently poorly understood. They likely result from a combination of genetic, environmental, proteomic and lipidomic factors that crucially occur only in the aged brain.
Green, Kim N
core +1 more source
Amyloid oligomer conformation in a group of natively folded proteins. [PDF]
PLoS ONE, 2008 Recent in vitro and in vivo studies suggest that destabilized proteins with defective folding induce aggregation and toxicity in protein-misfolding diseases.
Yuji Yoshiike +5 more
doaj +1 more source